



Denys Wheatley
Editor.

Oncology News – Moving Forward into 2018 The ‘oncologynews’ team

The previous editorial brought you up to date with the position the journal was in as it went through transition. The good news is that an excellent management team has been brought together, about which there will be more as we get the January/February issue together (volume 13 (1), 2018). It has been a tough task to get everything transferred to the team over the last six weeks, which is why the last issue (November/December, 2017 – volume 12 (4)) will only be appearing in mid-January. One of our most difficult problems has been getting the emails of all readers and subscribers updated, which now numbers about 7,000. As we go global, this number should increase significantly during 2018.

For our online publication, <https://www.oncologynews.biz>, we will continue to include advertisements, event notices and reports, information on cancer charities, comments on topical news, diaries, reviews of pertinent research papers and books; all of these will be in addition to our core of regular articles on all aspects of cancer and cancer-related topics. For example, cancer-care professionals will value the magazine's practical and accessible approach, a popular way to keep up-to-date with the latest

developments in such aspects as care of the skin in some cancerous conditions, or special massage techniques. Our portal for submissions is editor@oncologynews.biz.

Apart from articles, a small handling fee will have to be charged for most of these items other than commercial advertising, for which a rate card is available on request. We can also assist your immediate needs with a fast track mailshot to our subscribers. For more information, contact our Marketing and Advertising Manager at info@oncologynews.biz.

Oncology News has an excellent following, with contributions from many different experts and authorities. Its assistant editor is Dr Richard Ablyn, discoverer of prostate specific antigen, unfortunately and misleadingly misnamed in Roswell Park Cancer Institute as prostate cancer specific antigen. It is only a corollary factor in the possibility that malignant changes might be occurring in the prostate gland. Our neuro-oncology section is looked after by Professor Geoff Pilkington. We will have many more expert panels in the coming years from all part of the world on the vast range different malignancies that continue to plague mankind, i.e. watch this space!

Denys Wheatley

Professor Denys Wheatley, BSc (Lond), PhD, DSc, MD (multi h.c.), CIBiol, FRSB, FCPATH, is Chairman and Director of BioMedES UK, and is now in charge of the management team publishing *Oncology News* under the auspices of his company. BioMedES (pronounced like Archimedes) also publishes another online journal, *Cancer Hypotheses*, the content of which is theoretical papers on all aspect of cancer from carcinogenesis to the putative mechanism of the action of anti-cancer drugs and other interventions. It acts as a forum for debate, with articles having critical comments on old or extant theories, and particularly welcomes papers positing new hypotheses.

Denys has a long history of editing scientific and medical journals ever since his postgraduate days in the Institute of Cancer Research (The Chester Beatty) in London. He ran *Cell Biology International* for over 16 years, and founded two online journals in the early days of online publishing through BioMed Central (*Cancer Cell International* and *Theoretical Biology and Medical Modelling*). In 1998 he formed Cancer Treatments International with Dr Slobodan Tepic (Davos and Zürich), before it became Bio-Cancer Treatments International in Hong Kong, for which he was Chief Scientific Officer for its first 10 years. The development from it of pegylated L-arginase in the treatment of hepatocellular carcinoma,

melanoma and AML is now undergoing further trials in the USA and UK, as well as Hong Kong. He also perceptively noted the role of the primary cilium as a major player in cell sensory activity, and the fact that its dysfunction would result in pathological conditions. It is now implicated in -50 disorders, from polycystic kidney disease to dementia, although this cellular organelle had for the best part of a century been considered rudimentary or vestigial.

His research has taken him all over the world, often in recent times to Hungary, Brazil, Russia, Ukraine and USA. He continues to collaborate with colleagues worldwide in the development of new cancer treatments. In publishing and scientific communication, he has taught courses in about 20 different countries on *Scientific Writing and Publishing* (his Manual of this title is available on Amazon Kindle). As well as receiving international awards for his research and many offices in international and national organisations, he has received three doctorates (honoris causa), published over 350 papers and 6 books, with two more in preparation. As an artist, he has given many exhibitions, especially in helping people needing art in therapy or mental health recovery. He plays (cello) regularly with the Aberdeen Chamber Orchestra and the European Doctors Orchestra, and performed in the inaugural and second concert of the World Doctors Orchestra in Berlin and Cleveland, respectively.

